MX386901B - Formulacion que contiene una gran cantidad de compuesto tetraciclico. - Google Patents

Formulacion que contiene una gran cantidad de compuesto tetraciclico.

Info

Publication number
MX386901B
MX386901B MX2016013809A MX2016013809A MX386901B MX 386901 B MX386901 B MX 386901B MX 2016013809 A MX2016013809 A MX 2016013809A MX 2016013809 A MX2016013809 A MX 2016013809A MX 386901 B MX386901 B MX 386901B
Authority
MX
Mexico
Prior art keywords
formulation containing
large amount
tetracyclic compound
salt
compound
Prior art date
Application number
MX2016013809A
Other languages
English (en)
Other versions
MX2016013809A (es
Inventor
Kensuke Okazaki
Takahiro Yamamura
Takashi Tomimatsu
Yumi Ogawa
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54332608&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX386901(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MX2016013809A publication Critical patent/MX2016013809A/es
Publication of MX386901B publication Critical patent/MX386901B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Una composición o formulación farmacéutica que contiene una gran cantidad de 9-etil-6,6-dimetil-8-(4-morfolin-4-il-piperidin-1-il)-11-oxo-6,11-dihidro-5H-benzo[b]carbazol-3-carbonitrilo o una sal del mismo con solubilidad mejorada que puede obtenerse formando granulados del compuesto o una sal del mismo y mezclando los granulados con un agente desintegrante.
MX2016013809A 2014-04-25 2015-04-24 Formulacion que contiene una gran cantidad de compuesto tetraciclico. MX386901B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014092101 2014-04-25
PCT/JP2015/062520 WO2015163448A1 (ja) 2014-04-25 2015-04-24 ４環性化合物を高用量含有する製剤

Publications (2)

Publication Number Publication Date
MX2016013809A MX2016013809A (es) 2017-03-09
MX386901B true MX386901B (es) 2025-03-19

Family

ID=54332608

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016013809A MX386901B (es) 2014-04-25 2015-04-24 Formulacion que contiene una gran cantidad de compuesto tetraciclico.
MX2021012300A MX2021012300A (es) 2014-04-25 2016-10-20 Formulacion que contiene una gran cantidad de compuesto tetraciclico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021012300A MX2021012300A (es) 2014-04-25 2016-10-20 Formulacion que contiene una gran cantidad de compuesto tetraciclico.

Country Status (19)

Country Link
US (4) US10350214B2 (es)
EP (2) EP4397659A3 (es)
JP (2) JP5859712B1 (es)
KR (2) KR102478887B1 (es)
CN (2) CN113975243A (es)
AR (2) AR100187A1 (es)
AU (2) AU2015250574B2 (es)
BR (1) BR112016021206B1 (es)
CA (2) CA3140565C (es)
ES (1) ES2994202T3 (es)
IL (2) IL248363B (es)
MX (2) MX386901B (es)
MY (2) MY189913A (es)
PL (1) PL3135287T3 (es)
RU (2) RU2724056C2 (es)
SG (2) SG10202009484WA (es)
TW (3) TWI831128B (es)
WO (1) WO2015163448A1 (es)
ZA (1) ZA201606447B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2668775T3 (es) * 2009-06-10 2018-05-22 Chugai Seiyaku Kabushiki Kaisha Compuestos tetracíclicos
MX355836B (es) 2010-08-20 2018-05-02 Chugai Pharmaceutical Co Ltd Composicion que comprende compuestos tetraciclicos.
US10668075B2 (en) 2012-09-25 2020-06-02 Chugai Seiyaku Kabushiki Kaisha RET inhibitor
KR101974254B1 (ko) 2013-07-18 2019-04-30 다이호야쿠힌고교 가부시키가이샤 Fgfr 저해제의 간헐 투여용 항종양제
WO2015008844A1 (ja) 2013-07-18 2015-01-22 大鵬薬品工業株式会社 Ｆｇｆｒ阻害剤耐性癌の治療薬
WO2015163448A1 (ja) * 2014-04-25 2015-10-29 中外製薬株式会社 ４環性化合物を高用量含有する製剤
TWI831347B (zh) 2014-08-08 2024-02-01 日商中外製藥股份有限公司 包含４環性化合物的非晶質體之固體分散體及製劑
JP6741596B2 (ja) 2015-01-16 2020-08-19 中外製薬株式会社 併用医薬
MX373612B (es) 2015-03-31 2020-05-07 Taiho Pharmaceutical Co Ltd Cristal del compuesto alquinil benceno 3,5-disustituido.
EP3424505A4 (en) 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
JP7172997B2 (ja) * 2017-04-28 2022-11-16 アステラス製薬株式会社 エンザルタミドを含有する経口投与用医薬組成物
EP4470621A3 (en) 2018-03-19 2025-05-07 Taiho Pharmaceutical Co., Ltd. Use of sodium alkyl sulfate
CN112384223B (zh) * 2018-06-29 2024-08-27 中外制药株式会社 含有难溶性碱性药剂的药物组合物
WO2020050241A1 (ja) 2018-09-04 2020-03-12 中外製薬株式会社 ４環性化合物の製造方法
AR121187A1 (es) * 2019-12-27 2022-04-27 Chugai Pharmaceutical Co Ltd Método para clasificar, evaluar o fabricar lauril sulfato de sodio de materia prima o formulación farmacéutica que lo contiene
CN112218626B (zh) * 2019-12-31 2023-03-24 广州帝奇医药技术有限公司 一种持续释放组合物及其制备方法
AU2022215105A1 (en) * 2021-01-29 2023-07-20 Chugai Seiyaku Kabushiki Kaisha Drug composition for treating pediatric cancers
WO2023074785A1 (ja) 2021-10-28 2023-05-04 中外製薬株式会社 シロップ剤
AU2024332707A1 (en) 2023-08-31 2026-02-19 F. Hoffmann-La Roche Ag Treatment of non small cell lung cancer with alectinib
WO2025104045A1 (en) 2023-11-15 2025-05-22 F. Hoffmann-La Roche Ag Alectinib for the treatment of alk fusion-positive solid or cns tumours

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4918630B1 (es) 1970-07-29 1974-05-11
US5028433A (en) 1988-11-30 1991-07-02 Banyu Pharmaceutical Co., Ltd. Readily absorbable drug formulation of NB-818
JPH0667840B2 (ja) 1988-11-30 1994-08-31 萬有製薬株式会社 Ｎｂ―８１８の易吸収性製剤
JPH0892090A (ja) 1994-07-26 1996-04-09 Tanabe Seiyaku Co Ltd 医薬組成物
ES2123873T3 (es) 1994-08-04 1999-01-16 Hoffmann La Roche Pirrolocarbazol.
JPH09202728A (ja) 1995-12-11 1997-08-05 Hisamitsu Pharmaceut Co Inc 固形製剤
EA001450B1 (ru) 1996-05-01 2001-04-23 Эли Лилли Энд Компани Галогензамещенные ингибиторы протеинкиназы с
EP1178988B1 (en) 1999-05-14 2007-02-28 The Australian National University Compounds and therapeutic methods
CA2430288C (en) 2000-12-01 2009-03-10 Kyowa Hakko Kogyo Co., Ltd. A composition improved in the solubility or oral absorbability
GB0030417D0 (en) 2000-12-13 2001-01-24 Pharma Mar Sa An anticancer lead compound isolated from a New Zealand ascidian
FR2841138B1 (fr) 2002-06-25 2005-02-25 Cll Pharma Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation
US7807197B2 (en) 2002-09-28 2010-10-05 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion
KR20050118169A (ko) 2003-02-28 2005-12-15 이노텍 파마슈티컬스 코포레이션 사환식 벤즈아미드 유도체 및 이것의 사용 방법
PT1454992E (pt) 2003-03-07 2006-09-29 Ist Naz Stud Cura Dei Tumori Ensaio de quinase do linfoma anaplastico, reagentes e composicoes
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
AU2004259012C1 (en) 2003-07-23 2012-08-02 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US7378414B2 (en) 2003-08-25 2008-05-27 Abbott Laboratories Anti-infective agents
EP1671962A1 (en) 2003-10-10 2006-06-21 Ono Pharmaceutical Co., Ltd. Novel fused heterocyclic compound and use thereof
JP2007511575A (ja) 2003-11-21 2007-05-10 ノバルティス アクチエンゲゼルシャフト タンパク質キナーゼ阻害剤としての１ｈ−イミダゾキノリン誘導体
CA2548600A1 (en) 2003-12-12 2005-06-23 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
CA2560195A1 (en) 2004-03-19 2005-09-29 Speedel Experimenta Ag Organic compounds
US7973061B2 (en) 2004-03-31 2011-07-05 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
GEP20104906B (en) 2004-08-26 2010-02-25 Pfizer Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
US7091202B2 (en) 2004-09-15 2006-08-15 Bristol-Myers Squibb Company 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators
GB0423964D0 (en) * 2004-10-28 2004-12-01 Jagotec Ag Dosage form
GB0517329D0 (en) 2005-08-25 2005-10-05 Merck Sharp & Dohme Stimulation of neurogenesis
CN101304993A (zh) 2005-11-07 2008-11-12 Irm责任有限公司 作为ppar调节剂的化合物和组合物
KR101146852B1 (ko) 2005-12-05 2012-05-16 화이자 프로덕츠 인크. Ｃ?ｍｅｔ／ｈｇｆｒ 억제제의 다형체
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
KR101435229B1 (ko) * 2006-09-14 2014-08-28 아스테라스 세이야쿠 가부시키가이샤 구강내 붕괴정 및 그 제조법
CA2598893C (en) 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
EP1914240B1 (en) 2006-10-11 2009-12-02 Astellas Pharma Inc. EML4-ALK fusion gene
ES2555803T3 (es) 2006-10-23 2016-01-08 Cephalon, Inc. Fusión de derivados bicíclicos 2,4-diaminopirimidina como utilizar inhibidores ALK y c-Met
WO2008130951A1 (en) 2007-04-17 2008-10-30 Bristol-Myers Squibb Company Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors
TWI389893B (zh) 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
US8299057B2 (en) 2007-07-20 2012-10-30 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors
CN101932325B (zh) 2007-11-30 2014-05-28 新联基因公司 Ido抑制剂
US20090214648A1 (en) * 2008-02-15 2009-08-27 Malathi Kandakatla Pharmaceutical formulations comprising ibuprofen and diphenhydramine
ES2510866T3 (es) 2008-03-13 2014-10-21 Daiichi Sankyo Company, Limited Mejora de la solubilidad de una preparación que contiene olmesartán medoxomilo
US20100151034A1 (en) * 2008-09-30 2010-06-17 Astellas Pharma Inc. Granular pharmaceutical composition of atorvastatin for oral administration
AU2010244218B2 (en) 2009-05-07 2012-07-19 Astrazeneca Ab Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
ES2668775T3 (es) * 2009-06-10 2018-05-22 Chugai Seiyaku Kabushiki Kaisha Compuestos tetracíclicos
US20110311625A1 (en) * 2010-06-14 2011-12-22 Amruth Gowda Doddaveerappa Solid dosage forms of fenofibrate
MX355836B (es) * 2010-08-20 2018-05-02 Chugai Pharmaceutical Co Ltd Composicion que comprende compuestos tetraciclicos.
TWI564008B (zh) 2010-09-30 2017-01-01 鹽野義製藥股份有限公司 難溶性藥物之溶解性改善製劑
JP5006987B2 (ja) * 2010-11-22 2012-08-22 中外製薬株式会社 ４環性化合物を含む医薬
MX343509B (es) * 2011-04-06 2016-11-08 Dow Global Technologies Llc Proceso para producir derivados de celulosa de alta densidad aparente y buena fluidez.
AU2013243461A1 (en) * 2012-04-04 2014-11-06 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for combination therapy
US10668075B2 (en) 2012-09-25 2020-06-02 Chugai Seiyaku Kabushiki Kaisha RET inhibitor
US9381246B2 (en) * 2013-09-09 2016-07-05 Triact Therapeutics, Inc. Cancer therapy
EP3135671B1 (en) 2014-04-25 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Novel crystal of tetracyclic compound
WO2015163448A1 (ja) * 2014-04-25 2015-10-29 中外製薬株式会社 ４環性化合物を高用量含有する製剤
CN106456556A (zh) 2014-06-18 2017-02-22 豪夫迈·罗氏有限公司 包含非离子性表面活性剂的新型药物组合物
TWI831347B (zh) 2014-08-08 2024-02-01 日商中外製藥股份有限公司 包含４環性化合物的非晶質體之固體分散體及製劑

Also Published As

Publication number Publication date
CN106456651A (zh) 2017-02-22
TWI720943B (zh) 2021-03-11
AR132148A2 (es) 2025-05-28
IL283152B2 (en) 2023-05-01
EP4397659A2 (en) 2024-07-10
IL283152B1 (en) 2023-01-01
AU2015250574A1 (en) 2016-11-24
EP3135287A1 (en) 2017-03-01
SG10202009484WA (en) 2020-11-27
MX2021012300A (es) 2021-11-12
IL248363A0 (en) 2016-11-30
PL3135287T3 (pl) 2025-03-31
IL248363B (en) 2021-05-31
MY200583A (en) 2024-01-04
AU2020230293B2 (en) 2021-07-22
TWI771839B (zh) 2022-07-21
IL283152A (en) 2021-06-30
BR112016021206B1 (pt) 2022-07-12
KR20220087583A (ko) 2022-06-24
SG11201607623XA (en) 2016-11-29
AU2020230293A1 (en) 2020-10-01
TW202114693A (zh) 2021-04-16
TW201622706A (zh) 2016-07-01
MY189913A (en) 2022-03-21
JPWO2015163448A1 (ja) 2017-04-20
CA3140565C (en) 2022-10-11
BR112016021206A2 (es) 2017-08-15
AR100187A1 (es) 2016-09-14
CA2946518C (en) 2022-07-26
EP4397659A3 (en) 2024-10-02
RU2016145057A (ru) 2018-05-28
JP5859712B1 (ja) 2016-02-10
EP3135287A4 (en) 2018-01-03
CN113975243A (zh) 2022-01-28
US10350214B2 (en) 2019-07-16
CA3140565A1 (en) 2015-10-29
EP3135287C0 (en) 2024-11-20
US11433076B2 (en) 2022-09-06
AU2015250574B2 (en) 2020-07-16
US20170035773A1 (en) 2017-02-09
RU2724056C2 (ru) 2020-06-19
CA2946518A1 (en) 2015-10-29
KR20160146800A (ko) 2016-12-21
TWI831128B (zh) 2024-02-01
JP6129942B2 (ja) 2017-05-17
US20200038407A1 (en) 2020-02-06
KR102478887B1 (ko) 2022-12-16
US20230105990A1 (en) 2023-04-06
MX2016013809A (es) 2017-03-09
NZ724713A (en) 2023-09-29
TW202235088A (zh) 2022-09-16
RU2016145057A3 (es) 2018-11-09
ZA201606447B (en) 2019-09-25
RU2020119391A (ru) 2020-07-03
ES2994202T3 (en) 2025-01-20
US20220378800A1 (en) 2022-12-01
EP3135287B1 (en) 2024-11-20
JP2016104762A (ja) 2016-06-09
KR102412321B1 (ko) 2022-06-22
NZ763604A (en) 2023-09-29
WO2015163448A1 (ja) 2015-10-29

Similar Documents

Publication Publication Date Title
MX2016013809A (es) Formulacion que contiene una gran cantidad de compuesto tetraciclico.
CL2015003491A1 (es) Compuestos químicos.
SV2016005180A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
CL2017003258A1 (es) Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen
UY36342A (es) Nuevos derivados de aminoalquilbenzotiazepinas y usos de los mismos
CL2017003205A1 (es) Nuevos derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen.
CO2017001994A2 (es) Compuestos activos hacia bromodominios
SI3145934T1 (sl) Substituirane spojine -6,8-dioksabiciklo(3.2.1)oktan-2,3-diol kot zdravila, ki delujejo na ASGPR
CL2015001733A1 (es) Compuestos derivados de lactamas fusionadas de arilo y heteroarilo, moduladores de ezh2; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento del cancer.
CL2015002865A1 (es) Composiciones de limpieza que contienen una poliéteramina
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
UY36075A (es) Derivados de tubulisina
CL2016000148A1 (es) Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los contienen.
CU20150061A7 (es) PIRIMIDO-[4,5-b]-QUINOLINA-4,5(3H,10H)-DIONAS COMO SUPRESORAS DE MUTACIÓN SIN SENTIDO
SV2016005293A (es) Compuestos de azol amido-sustituidos como inhibidores de tnks1 y/o tnks2
PH12017500348A1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
CL2016002677A1 (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina d1.
DOP2015000298A (es) Compuestos nuevos para el tratamiento del cáncer
ECSP16096831A (es) Derivados de naftiridinadiona
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
MX2017002737A (es) Farmaceutico que contiene inhibidor de transportador de fosfato dependiente de sodio.
MX2016002931A (es) Moduladores del receptor x hepatico (lxr).
MX2016008406A (es) Preparacion farmaceutica combinada que comprende el bloqueante del receptor de la angiotensina ii y el inhibidor de la hmg-coa reductasa.
EP3418271A4 (en) Novel indole derivative and anti-cancer composition with it
CR20140051A (es) Compuestos de tiazol y oxazol de bencen-sulfonamida